| K-number | K243893 |
| Device name | Second Opinion® Pediatric |
| Applicant | Pearl, Inc. |
| Product code | MYN |
| Device class | Class II |
| Decision date | May 5, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 892.2070 |
Second Opinion® Pediatric is a computer-aided detection (CADe) software that uses machine learning to automatically detect and display caries (cavities) in bitewing and periapical dental radiographs. It is intended for patients aged 4 years and older with primary or permanent teeth to aid dental health professionals in their radiographic review, functioning as a second reader rather than replacing clinical judgment.
Both the subject device and predicate use neural network-based computer vision algorithms running on Windows operating systems to process digital intraoral radiographs and display detected caries as graphical overlays with near-instantaneous results. The key difference is that the subject device focuses exclusively on caries detection, whereas the predicate also detects dental restorations and other findings; however, this narrower scope does not raise safety or efficacy concerns.
Not stated in this summary. The document references verification and validation testing requirements and mentions FDA Guidance on Cybersecurity in Medical Devices (September 2023), but does not cite specific ISO, IEC, ASTM, or other consensus standards.
The device is substantially equivalent because it maintains the same intended use (aiding detection of caries in dental radiographs using machine learning), employs identical technology (neural network-based computer vision), and produces comparable clinical performance to the predicate. The expansion of the patient population from ages 12+ to 4+ years is supported by a standalone clinical study demonstrating lesion-level sensitivity of 87% (95% CI: 0.84–0.90), which meets the primary endpoint of >75% sensitivity and achieves performance metrics (wAFROC FOM 0.86, Dice Score 0.76) equivalent to the predicate's established performance.
View the full FDA submission: accessdata.fda.gov